Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Recovery after a major stroke is usually limited, but cell therapy for patients with fixed neurologic deficits is emerging. Several recent clinical trials have investigated mesenchymal stem cell (MSC) therapy for patients with ischemic stroke. We previously reported the results of a controlled trial on the application of autologous MSCs in patients with ischemic stroke with a long-term follow-up of up to 5 years (the 'STem cell Application Researches and Trials In NeuroloGy’ (STARTING) study). The results from this pilot trial are challenging, but also raise important issues. In addition, there have been recent efforts to improve the safety and efficacy of MSC therapy for stroke. Methods and design: The clinical and preclinical background and the STARTING-2 study protocol are provided. The trial is a prospective, randomized, open-label, blinded-endpoint (PROBE) clinical trial. Both acute and chronic stroke patients will be selected based on clinical and radiological features and followed for 3 months after MSC treatment. The subjects will be randomized into one of two groups: (A) a MSC group (n = 40) or (B) a control group (n = 20). Autologous MSCs will be intravenously administered after ex vivo culture expansion with autologous ischemic serum obtained as early as possible, to enhance the therapeutic efficacy (ischemic preconditioning). Objective outcome measurements will be performed using multimodal MRI and detailed functional assessments by blinded observers. Discussion: This trial is the first to evaluate the efficacy of MSCs in patients with ischemic stroke. The results may provide better evidence for the effectiveness of MSC therapy in patients with ischemic stroke. Trial registration: This trial was registered with ClinicalTrials.gov, number NCT01716481.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R., Carnethon, M., De Simone, G., Ferguson, T. B., Flegal, K., Ford, E., Furie, K., Go, A., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191261 · Cited by 3,140
Neuronal replacement from endogenous precursors in the adult brain after stroke
Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z., & Lindvall, O. (2002) · Nature Medicine · doi:10.1038/nm747 · Cited by 2,799 · cited 1×
“Newly born cells migrate to the stroke site, express neuronal and glial-specific phenotypic markers [17,18], and form synapses [19].”
BackgroundHypoxia enhances proliferation and tissue formation of human mesenchymal stem cells
Grayson, W. L., Zhao, F., Bunnell, B., & Ma, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.054 · Cited by 521
Cell transplantation therapy for stroke
Bliss, T., Guzman, R., Daadi, M., & Steinberg, G. K. (2007) · Stroke · doi:10.1161/01.str.0000247888.25985.62 · Cited by 374
Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke
Shen, L. H., Li, Y., Chen, J., Zacharek, A., Gao, Q., Kapke, A., Lu, M., Raginski, K., Vanguri, P., Smith, A., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600311 · Cited by 353
Hermann, D. M., & Chopp, M. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70039-x · Cited by 333 · cited 1×
“occlusion models [13].”
Contemporary Outcome Measures in Acute Stroke Research: Choice of Primary Outcome Measure
Lees, K. R., Bath, P. M. W., Schellinger, P. D., Kerr, D. M., Fulton, R., Hacke, W., Matchar, D., Sehra, R., & Toni, D. (2012) · Stroke · doi:10.1161/strokeaha.111.641423 · Cited by 242 · cited 1×
“The mRS is the primary endpoint of most stroke clinical trials and shift analysis has advantages over the classical dichotomized method for interventions that confer a uniform and modest benefit to patients over a broad range of stroke severity [54,55].”
MethodStroke-induced neurogenesis in aged brain
Darsalia, V., Heldmann, U., Lindvall, O., & Kokaia, Z. (2005) · Stroke · doi:10.1161/01.str.0000173151.36031.be · Cited by 240
Treatment effects for which shift or binary analyses are advantageous in acute stroke trials
Saver, J. L., & Gornbein, J. (2009) · Neurology · doi:10.1212/01.wnl.0000341308.73506.b7 · Cited by 135
Cited by
Madrigal, M., Rao, K. S., & Riordan, N. H. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0260-8 · Cited by 615
Li, J., Zhang, Q., Wang, W., Lin, F., Wang, S., & Zhao, J. (2021) · Journal of Neurology · doi:10.1007/s00415-020-10138-5 · Cited by 128
Cell therapy for cerebral hemorrhage: Five year follow-up report
Chang, Z., Mao, G., Sun, L., Ao, Q., Gu, Y., & Liu, Y. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3811 · Cited by 34
Vargas-Rodríguez, P., Cuenca-Martagón, A., Castillo-González, J., Serrano-Martínez, I., Luque, R. M., Delgado, M., & González-Rey, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814117 · Cited by 25
Metadata
- Authors
- Kim, S. J., Moon, G. J., Chang, W. H., Kim, Y.-H., Bang, O. Y., & collaborators, F. T. S.-2. (. C. A. R. A. T. I. N.-2.
- Venue
- Trials
- Published
- 2013-10-01
- Volume
- 14
- Issue
- 1
- Pages
- 317-317
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2116568124
- Cited by
- 73
- References
- 9
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. https://app.cochat.ai/papers/10.1186/1745-6215-14-317
- The paper
- Kim, S. J., Moon, G. J., Chang, W. H., Kim, Y.-H., Bang, O. Y., & collaborators, F. T. S.-2. (. C. A. R. A. T. I. N.-2. (2013). Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Trials. https://doi.org/10.1186/1745-6215-14-317
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.